Elliot Hershberg’s Post

View profile for Elliot Hershberg

Biotech Scientist, Writer, Investor

Solugen's announcement of their conditional loan from the DOE is one of the most encouraging pieces of synbio news I've heard in a while. I don't know the full details, but this type of financing indicates they sufficiently proved the repeatability/scalability of their forges. For an industry that's been plagued with issues involving scale-up, this is a pretty big deal. Congrats Gaurab and Sean! If you want to learn more about Solugen's story, you can check out my piece on them from last year: https://lnkd.in/ghaQqr87 It's interesting to note that one of the synbio companies most aggressively scaling is based on cell-free technology. Niko McCarty and I covered this in our piece on alternatives to fermentation-based bioproduction: https://lnkd.in/g_7-eW3G Finally, I think this is a really interesting example of financing the development of new facilities with non-equity instruments once the TEA and feasibility at scale have been validated. More on this concept here: https://lnkd.in/gib4TTMc

  • timeline

I agree! A nice step forward. Congrats to the U.S. Department of Energy (DOE) for their work in growing the bioeconomy and helping it scale.

Like
Reply

Thanks @ElliotHershberg! This definitely isn’t a silver bullet for the industry given how bespoke bio manufacturing can be, but it begins to create a risk management framework to assess these projects for bankability.

See more comments

To view or add a comment, sign in

Explore topics